Interestingly, we observed HuR downregulation in MDA-MB-231/doxoR but not in SK-BR-3/NOdoxoR (Figure 6B), suggesting that breast cancer cells downregulate HuR expression only when a deep genetic reprogramming towards pharmacoresistance is taking place and not as a consequence of the mere presence of doxo. This evidence concerns the gene ELAVL1 and breast cancer.